We recently acquired Cartox, a technology transfer company formed out of the University of Michigan and the Frankel Cardiovascular Center by Drs. Todd Herron and José Jalife. We believe this technology holds significant commercial promise for applications in both pre-clinical cardiotoxicity testing as well as the potential to revolutionize the cardiac drug efficacy screening process.

Cartox scientists demonstrated that a novel form of our CELLvo™ Matrix technology offers a unique environment for cardiomyocytes (heart muscle cells) differentiated from induced pluripotent stem cells that are used in drug safety testing.

For more information, send us an email or call +1 (210) 877-9323. During the next few weeks, stay tuned and we'll announce new products and capabilities.

In the meantime, check out our CELLvo™ Cells!!!  Our primary cells have been isolated using our CELLvo™ Matrix products. Ask about new promotions and special offers.  

We look forward to hearing from you as well as meeting your cell culture needs.  Thank you! 

The StemBioSys team